Start with its own history
At 12.76×, MLAB is 97.1% below its 7-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
NASDAQ · MLABMedical - SpecialtiesUpdated Nov 2, 2026
Mesa Laboratories, Inc. P/E ratio
Current valuation, historical context, and peer comparisons.
Current P/E ratio
12.76×
97.1% belowthe 7-observation annual average
Share price126.41
÷Earnings per share9.91
Price and EPS in quote currency. Calculation details
Investors are paying 12.76 for every 1 of reported earnings per share.
P/E over time
2017 – 2026
Annual P/ESelected-period average 434.50×
3-year average72.48×1 positive annual observations
5-year average602.77×3 positive annual observations
10-year average434.50×7 positive annual observations
Peer median · TTM40.51×6 peers with positive P/E
Historical P/E ratios
Annual period-end data · 25 observations
| Period end | P/E | Change |
|---|---|---|
| Mar 31, 2026 | 72.48× | N/M |
| Mar 31, 2025 | N/M | N/M |
| Mar 31, 2024 | N/M | N/M |
| Mar 31, 2023 | 1027.82× | +45.2% |
| Mar 31, 2022 | 708.00× | +91.9% |
| Mar 31, 2021 | 368.94× | -47.8% |
| Mar 31, 2020 | 706.53× | +501.9% |
| Mar 31, 2019 | 117.38× | N/M |
View all 25 annual observations +
| Period end | P/E | Change |
|---|---|---|
| Mar 31, 2018 | N/M | N/M |
| Mar 31, 2017 | 40.36× | +29.9% |
| Mar 31, 2016 | 31.08× | +17.1% |
| Mar 31, 2015 | 26.54× | -23.2% |
| Mar 31, 2014 | 34.58× | +68.1% |
| Mar 31, 2013 | 20.58× | +0.5% |
| Mar 31, 2012 | 20.46× | +35.7% |
| Mar 31, 2011 | 15.08× | -13.5% |
| Mar 31, 2010 | 17.42× | +64.4% |
| Mar 31, 2009 | 10.60× | -29.5% |
| Mar 31, 2008 | 15.02× | -1.2% |
| Mar 31, 2007 | 15.20× | +1.3% |
| Mar 31, 2006 | 15.01× | -17.0% |
| Mar 31, 2005 | 18.09× | +32.6% |
| Mar 31, 2004 | 13.64× | +46.4% |
| Mar 31, 2003 | 9.32× | -26.4% |
| Mar 31, 2002 | 12.67× | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
How MLAB compares
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
 MLAB This stockMesa Laboratories, Inc. | 12.76× |
 BIOBio-Rad Laboratories, Inc. | 44.97× |
 RVTYRevvity, Inc. | 73.05× |
 TMOThermo Fisher Scientific Inc. | 36.05× |
 QGENQiagen N.V. | 25.85× |
 AAgilent Technologies, Inc. | 34.03× |
 TECHBio-Techne Corporation | 62.14× |
 MRVIMaravai LifeSciences Holdings, Inc. | N/M |
 LABStandard BioTools Inc. | N/M |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
What does MLAB’s P/E tell you?
Compare like with like
The median of the 6 positive peer ratios above is 40.51×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
Check what drives earnings
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Take MLAB into your spreadsheet
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore WisesheetsQuarterly P/E · latest quarterLQ selects the latest reported quarter. Requires the Wisesheets add-in. See available data
=WISE("MLAB", "PE Ratio", "LQ")Sources & calculation methodology
Current P/E
Share price 126.41 ÷ EPS 9.91 = 12.76×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Nov 2, 2026; this is not a real-time trading quote.
History & averages
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
Data definitions and limitations
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
MLAB P/E ratio: common questions
The essentials behind the numbers.
Mesa Laboratories, Inc.'s current P/E is 12.76× based on the quote data last updated Nov 2, 2026. It represents the share price divided by reported earnings per share. Prices and earnings may refresh on different schedules.
Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.
N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.
Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.
Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.
Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.